0SZI Stock Overview A biopharmaceutical company, develops products to defeat serious illness. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Corbus Pharmaceuticals Holdings, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Corbus Pharmaceuticals Holdings Historical stock prices Current Share Price US$12.74 52 Week High US$61.81 52 Week Low US$5.31 Beta 2.57 1 Month Change -28.04% 3 Month Change -39.24% 1 Year Change 137.15% 3 Year Change -34.02% 5 Year Change -90.63% Change since IPO -93.25%
Recent News & Updates
Corbus Pharmaceuticals Announces Dosing of First Patient in Its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors Dec 10
Corbus Pharmaceuticals' CRB-701 Receives FDA Fast Track Designation for Metastatic Cervical Cancer Treatment Dec 04
Corbus Pharmaceuticals Holdings, Inc. Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024 Nov 05
Corbus Pharmaceuticals Holdings, Inc. Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) Oct 16
Corbus Pharmaceuticals Holdings, Inc. Announces Board and Committee Changes Aug 20
Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 16, 2024 Apr 03 See more updates
Corbus Pharmaceuticals Announces Dosing of First Patient in Its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors Dec 10
Corbus Pharmaceuticals' CRB-701 Receives FDA Fast Track Designation for Metastatic Cervical Cancer Treatment Dec 04
Corbus Pharmaceuticals Holdings, Inc. Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024 Nov 05
Corbus Pharmaceuticals Holdings, Inc. Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) Oct 16
Corbus Pharmaceuticals Holdings, Inc. Announces Board and Committee Changes Aug 20
Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 16, 2024 Apr 03
Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC Apr 02 Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Mar 21
Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Mar 14
Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer Mar 01
Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024 Feb 07
New major risk - Shareholder dilution Feb 02 Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million. Feb 02
Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million. Feb 01
New major risk - Shareholder dilution Feb 01 Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering.
Corbus Pharmaceuticals Holdings, Inc. Announces Data from the First-in-Human Clinical Study of CRB-701 (SYS6002) Jan 26 Nasdaq Gants Corbus Pharmaceuticals Holdings an Extension Until May 8, 2024 to Regain Compliance
Corbus Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Capital Market, Under Listing Rule 5550(b)(1) Nov 14
Corbus Pharmaceuticals Holdings, Inc. Presents Results of Two Pre-Clinical Studies on its Anti-VETA>8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting Nov 03
New minor risk - Shareholder dilution Jun 15
Corbus Pharmaceuticals Holdings, Inc. Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting Nov 11
Corbus Pharmaceuticals Holdings, Inc. Appoints Anne Altmeyer to Board of Directors Sep 27
First half 2022 earnings released: US$0.18 loss per share (vs US$0.28 loss in 1H 2021) Aug 11
Corbus Pharmaceuticals Holdings Gets a 180-Day Extension to January 2, 2023, to Regain Compliance with the Minimum Bid Price Requirement Jul 08
Corbus Pharmaceuticals Holdings, Inc. Enters into a Binding Term Sheet with Venn Therapeutics, LLC, to Resolve the Claims by Venn Against the Corbus Pharmaceuticals Holdings, Inc May 19
Corbus Pharmaceuticals Holdings, Inc. Announces That New Preclinical Data for CRB-601 Are Being Presented in an Oral Presentation At the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference in New York May 12
First quarter 2022 earnings released: US$0.075 loss per share (vs US$0.14 loss in 1Q 2021) May 11
Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 18, 2022 Apr 02
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 09
Corbus Pharmaceuticals Holdings Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market Jan 05
Third quarter 2021 earnings released: US$0.017 loss per share (vs US$0.43 loss in 3Q 2020) Nov 13
Head of Research & Chief Medical Officer Barbara White has left the company Sep 23
Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.52 loss in 2Q 2020) Aug 18 Corbus Pharmaceuticals Holdings, Inc.(NasdaqGM:CRBP) dropped from Russell 3000E Growth Index
Corbus Pharmaceuticals Announces Topline Results from Determine Phase 3 Study of Lenabasum for Treatment of Dermatomyositis Jun 25
Corbus Pharmaceuticals Holdings, Inc. Announces Licensing Deals for Two New Monoclonal Antibodies, CRB-601 and CRB-602 to Further Expand Pipeline into Cancer and Fibrotic Diseases Jun 02
Forecast to breakeven in 2024 May 16
First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.43 loss in 1Q 2020) May 16
Full year 2020 earnings released: US$1.42 loss per share (vs US$1.12 loss in FY 2019) Mar 16
Corbus Pharmaceuticals Holdings, Inc. Provides Clinical Program Updates Mar 16
Corbus Pharmaceuticals Holdings, Inc. to Report Q4, 2020 Results on Mar 15, 2021 Mar 09
New 90-day high: US$2.78 Feb 10
New 90-day high: US$2.04 Jan 21
Corbus Pharmaceuticals Holdings, Inc. Announces the Resignation of Robert Discordia as Chief Operating Officer Dec 06
Corbus Pharmaceuticals Holdings, Inc. Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis Nov 11
Corbus Pharmaceuticals Holdings, Inc. to Report Q3, 2020 Results on Nov 10, 2020 Nov 05 Robert Discordia Will No Longer Serve as Chief Operating Officer of Corbus Pharmaceuticals Holdings, Inc
Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint Oct 07
First half earnings released Aug 07
Corbus Pharmaceuticals Holdings, Inc. to Report Q2, 2020 Results on Aug 06, 2020 Jul 31 Shareholder Returns 0SZI GB Biotechs GB Market 7D -10.3% -5.0% -1.9% 1Y 137.2% -24.4% 2.6%
See full shareholder returns
Return vs Industry: 0SZI exceeded the UK Biotechs industry which returned -24.4% over the past year.
Return vs Market: 0SZI exceeded the UK Market which returned 2.6% over the past year.
Price Volatility Is 0SZI's price volatile compared to industry and market? 0SZI volatility 0SZI Average Weekly Movement 8.6% Biotechs Industry Average Movement 6.9% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.7% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0SZI's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0SZI's weekly volatility has decreased from 48% to 9% over the past year, but is still higher than 75% of UK stocks.
About the Company Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.
Show more Corbus Pharmaceuticals Holdings, Inc. Fundamentals Summary How do Corbus Pharmaceuticals Holdings's earnings and revenue compare to its market cap? 0SZI fundamental statistics Market cap US$160.28m Earnings (TTM ) -US$38.70m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0SZI income statement (TTM ) Revenue US$0 Cost of Revenue US$30.41m Gross Profit -US$30.41m Other Expenses US$8.29m Earnings -US$38.70m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 16:23 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Corbus Pharmaceuticals Holdings, Inc. is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kalpit Patel B. Riley Securities, Inc. George Zavoico B. Riley Securities, Inc. Kumaraguru Raja Brookline Capital Markets
Show 17 more analysts 
